CEMIP and breast cancer: We noticed that CEMIP was highly expressed in HER2+ and TNBC compared with luminal type and was expressed higher in the group of patients with an age over 51 years than those with an age less than 51, suggesting that CEMIP could be an indicator of aggressive types of BC, like HER2+ and TNBC, and might be responsible for some characteristics of invasive BC.